Patent intelligence · US
US 7943131
Methods for protecting and regenerating bone marrow using CXCR3 agonists and antagonists
Methods for protecting and regenerating bone marrow using CXCR3 agonists and antagonists
Patent details — US 7943131
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 17, 2011
- Expiration
- May 12, 2031
- Applicant
- GENERAL REGENERATIVES, LTD.
- Claims
- 5
- CPC classes
- A61K, A61K31/00, A61K31/255, A61K31/437
Quick answer
US 7943131 (Methods for protecting and regenerating bone marrow using CXCR3 agonists and antagonists) is held by GENERAL REGENERATIVES, LTD.. Status: granted. Granted May 17, 2011. Expires May 12, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GENERAL REGENERATIVES, LTD.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/00, A61K31/255, A61K31/437, A61K31/505, A61K31/519
More from GENERAL REGENERATIVES, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 7943131?
US 7943131 (Methods for protecting and regenerating bone marrow using CXCR3 agonists and antagonists) is held by GENERAL REGENERATIVES, LTD.. Status: granted. Granted May 17, 2011. Expires May 12, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7943131?
GENERAL REGENERATIVES, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 7943131 expire?
Our index shows an expiration date of May 12, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.